Biohaven Ltd. (BHVN) Institutional Investor Snapshot (297 Funds, Q2 2026)

BHVN ranks #2148 out of 37696 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

BHVN is a top-conviction position for Royalty Pharma Sub-Manager, LLC — at 18.1% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in BHVN belongs to BlackRock, Inc., but the position matters far more to Royalty Pharma Sub-Manager, LLC, who has 18.1% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

C2P Capital Advisory Group, LLC d.b.a. Prosperity Capital Advisors has added to its BHVN position for two straight quarters, increasing it by $102.5K to reach $233.6K today.

Essential Partners LLC has trimmed its BHVN position for two straight quarters, cutting it by $32.3K while still holding $44.1K.

BHVN is down 5.7% today, but institutions show net buying of $273.4M this quarter — a divergence between today's price move and the underlying institutional flow.

BHVN reported a net loss of $738.8M in its latest fiscal year.

• Not yet profitable — net loss of $738.8M in the latest fiscal year
• Net income improved year over year, from -$846.4M to -$738.8M
• Operating cash flow was negative, using $609.4M in cash
• Current ratio of 3.18x — enough short-term assets to cover short-term liabilities
• Liabilities run 7.67x equity — a highly leveraged balance sheet worth noting